Axis Securities and JM Financial both maintain 'Buy' ratings on Biocon, with target prices of Rs 370 and Rs 380, respectively. Biocon has a strong product pipeline, including new offerings expected to drive growth. The company is also refinancing debt to lower costs and exploring fund-raising options through asset sales. Positive growth is anticipated in the biosimilars business starting in 2H FY25.
